"I see a future now in the present: that people aren't flooding the emergency rooms with complaints related to diabetes and obesity. These are problems they can solve, but they can solve them only when they have the information more immediately at their disposal and also in real time -- and that's something we're trying to solve for. If we can do that, then our primary care physicians are focused on more advanced problems and actually practicing preventative care, not being so reactionary. We're just unclogging the system. People don't wanna be in doctor's offices. They don't want to be there, but they kinda have to be -- until something like this is available to them. Credit to Dexcom and Abbott for putting glucose monitors out there. It's clearly a helpful technology, but now we have to scale it. And in order to scale it, you really have to reinvent it... and listen to the user and understand what they're looking for. That's the future that we're trying to create."

That future is what Casey Halpern, MD, Founder & Chairman of SynchNeuro, has been building toward -- and it is closer now than it has ever been.

For most of SynchNeuro's early history, the technology existed primarily in published research, academic discovery, and the labs at Stanford where Dr. Halpern’s team first identified the link between brain signals and blood sugar. Now it lives in a small, flexible adhesive patch worn by every member of the company's team.

That shift -- from concept to working prototype to active internal alpha test -- is the kind of inflection point that is easy to understate and hard to overstate. SynchNeuro's device is a miniaturized EEG sensor housed in a skin-toned patch that sits in the naturally hairless area behind the ear. “Think of it like a BandAid that sits behind your ear,” says Dr. Halpern. It contours to the skull, is soft enough to sleep on, and is compatible with glasses, sunglasses, and hearing aids. It is designed for continuous wear, potentially for years at a time, generating the kind of longitudinal health data that no current wearable captures in the same way.

The internal alpha is generating real feasibility and usability feedback from a team that Dr. Halpern characterizes as skeptical scientists and their own most rigorous critics. And even by that standard, the early signal is compelling. In algorithm training runs with approximately 20 subjects, the platform's glucose readings approached the accuracy of Dexcom's devices. Dr. Halpern attributes this not to exceptional circumstances, but to the inherent robustness of the brain's metabolic signaling -- a biological function shaped over millennia, when the brain needed to orchestrate the body's response to food scarcity. That function is still there. Now there are machine learning tools sophisticated enough to read it from a sensor the size of a bandage.

Traditional continuous glucose monitors like those from Dexcom and Abbott provide a single continuous data stream: blood glucose. They are invasive, expensive, and limited in scope. SynchNeuro's platform is designed to decode multiple health signals from the same EEG data -- sleep quality, heart rate, heart rate variability, physical activity, and stress -- and synthesize them into guidance that helps users get ahead of problems before they happen.

The most distinctive expression of this is what Dr. Halpern describes as a daily glucose stability score, delivered each morning based on the prior night's sleep data. Think of it as a weather forecast for your metabolism. The score reflects the blood sugar trajectory the platform anticipates for the day. It updates as behavior unfolds. Go for a run, and it improves. Lean into a high-carbohydrate morning, and it reflects that too. Users receive actionable guidance -- on exercise, food choices, stress management -- tailored to where their score stands and where it is headed.

“It's not telling people that they just made a mistake. We want to get ahead -- helping them prevent the problem before it becomes a problem.”

The insight powering this feature is one of SynchNeuro's most compelling early findings: sleep quality sets a physiological ceiling on how high blood sugar can rise, and the brain's electrical activity during sleep encodes that information in a way the platform's algorithm can reliably decode.

To connect dietary choices to metabolic outcomes, the company has also partnered with January AI, enabling an automated food diary within the platform that helps users trace unexpected sources of blood sugar spikes -- including hidden additives in foods that seem healthy on the surface -- and understand what is actually driving their patterns.

Within weeks of this conversation, SynchNeuro is preparing to launch an IRB-approved human clinical study. Technically classified as a clinical trial due to the involvement of human subjects, it is functionally an algorithm training exercise: participants wear the device, generating the longitudinal EEG and glucose data the platform's machine learning models need to improve and generalize. Hundreds of participants are anticipated over a training period of approximately three to six months.

Following that training, SynchNeuro plans to apply for an Investigational Device Exemption through the FDA and pursue over-the-counter 510(k) clearance. The team already has a clear picture of the clinical evidence required. A commercial launch -- available over the counter, the kind of thing you could walk into a pharmacy and buy -- is targeted for late 2027 to early 2028.

Dr. Halpern calls that chapter one. The roadmap beyond it includes the brain-cardiac axis, leveraging the brain's role in anticipating cardiovascular events to build toward stroke and heart attack prediction. Women's health and hormonal tracking are also in view, though currently constrained by the absence of a real-time continuous hormone monitor that could serve as a training reference dataset.

Dr. Halpern is quick to credit his co-founder and company president, Emily Mirro, with building the team and culture that makes execution like this possible. "I couldn't be prouder or more inspired," he says. The team's ability to consistently deliver on what it promises has been central to SynchNeuro's story.

The deeper ambition is the redefinition of preventative medicine. An estimated 40 to 50 million Americans have prediabetes, and many are told by their physicians that they are not sick enough to warrant specialist attention. Dr. Halpern pushes back on the framing: "This is not a population of people that has given up." They are among the most motivated health consumers in the country, and SynchNeuro is building for them first. If it succeeds at scale, the downstream effects could include fewer diabetes-related emergency room visits, primary care physicians freed to practice genuine preventative care rather than reactive management, and a healthcare system less overwhelmed by a crisis that, in many cases, was not inevitable.

As the user base grows, the platform's machine learning improves -- a virtuous cycle in which more users directly enhance the value of the product for everyone in the community. That is not just a product feature. It is a model for what health technology can be when it is built around collective progress rather than individual transactions.

SynchNeuro is currently raising its seed round, and StartUp Health is proud to support the company's mission through its T1D Moonshot Fund, backed by the Helmsley Charitable Trust  -- and to have Casey Halpern, MD, and Emily Mirro as valuable members of the StartUp Health Community.